Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1715-1721

  Thomas, Cherry T ^b   Bradshaw, Patrick T ^b   Pollock, Brad H ^b   Montie, James E ^b   Taylor, Jeremy M G ^b   Thames, Howard D ^b   McLaughlin, Patrick W ^b   DeBiose, David A ^b   Hussey, David H ^b   Wahl, Richard L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; INDIUM MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; CAPROMAB PENDETIDE; DIAGNOSTIC AGENT; INDIUM;

CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOSCINTIGRAPHY; MALE; MEDICAL RECORD; METASTASIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; RADIOIMMUNOASSAY; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; ARTICLE; MIDDLE AGED; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK; SCINTISCANNING; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 0037797284     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.138     Document Type: Review

References (47)

1. Murphy GP, Elgamal AA, Troychak MJ, et al: Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 42:315-317, 2000
2. Murphy GP, Maguire RT, Rogers B, et al: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 33:281-285, 1997
3. Polascik TJ, Manyak MJ, Haseman MK, et al: Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 85:1586-1592, 1999
4. Sodee DB, Malguria N, Faulhaber P, et al: Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer: The ProstaScint Imaging Centers. Urology 56:988-993, 2000
5. Raj GV, Partin AW, Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94:987-996, 2002
6. Food and Drug Administration: Cytogen: SBA PLA 95-0041. Http://www.fda.gov/cber/sba/capcyt102896sba.pdf
7. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927-935, 1987
8. Troyer JK, Feng Q, Beckett ML, et al: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29-37, 1995
9. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232-242, 1997
10. Kahn D, Williams RD, Haseman MK, et al: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16:284-289, 1998
11. Levesque PE, Nieh PT, Zinman LN, et al: Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 51:978-984, 1998
12. Kahn D, Austin JC, Miller S, et al: In-111 capromab pendetide mab scan predicts response to radiotherapy to the prostate fossa in men with tumor recurrence following radical prostatectomy. J Urol 161:239, 1999 (suppl)
13. Forman JD, Duclos M, Shamsa F, et al: Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation. Urology 47:382-386, 1996
14. Schild SE, Buskirk SJ, Wong WW, et al: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 156:1725-1729, 1996
15. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19:1030-1039, 2001
16. McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 151:1575-1578, 1994
17. Seltzer MA, Barbaric Z, Belldegrun A, et al: Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162:1322-1328, 1999
18. Parker C, Warde P, Catton C: Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 61:107-116, 2001
19. Sodee DB, Conant R, Chalfant M, et al: Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the deteclion of recurrent prostate cancer. Clin Nucl Med 21:759-767, 1996
20. Anonymous: Consensus statement: Guidelines for PSA following radiation therapy-American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
23. Forman JD, Meetze K, Pontes E, et al: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 158:1436-1440, 1997
24. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001
25. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281:1591-1597, 1999
26. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994
27. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999
28. Graefen M, Karakiewicz PI, Cagiannos I, et al: Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 20:951-956, 2002
29. Suit HD, Gallager HS: Intact tumor cells in irradiated tissue. Arch Pathol 78:648-651, 1964
30. Bidart JM, Thuillier F, Augereau C, et al: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695-1707, 1999
31. Padhani AR, Gapinski CJ, Macvicar DA, et al: Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55:99-109, 2000
32. Petronis JD, Regan F, Lin K: Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 23:672-677, 1998
33. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: Current and future utility. Semin Urol Oncol 16:2-12, 1998
34. Rodwell JD, Alvarez VL, Lee C, et al: Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc Natl Acad Sci U S A 83:2632-2636, 1986
35. Lopes AD, Davis WL, Rosenstraus MJ, et al: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423-6429, 1990
36. Babaian RJ, Lamki LM: Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 19:309-321, 1989
37. Halpern SE, Hagan PL, Garver PR, et al: Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models. Cancer Res 43:5347-5355, 1983
38. Khaw BA, Cooney J, Edgington T, et al: Differences in experimental tumor localization of dual-labeled monoclonal antibody. J Nucl Med 27:1293-1299, 1986
39. Hinkle GH, Burgers JK, Neal CE, et al: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 83:739-747, 1998
40. Kahn D, Williams RD, Manyak MJ, et al: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159:2041-2047, 1998
41. Lange PH: ProstaScint scan for staging prostate cancer. Urology 57:402-406, 2001
42. Chang SS, Reuter VE, Heston WD, et al: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192-3198, 1999
43. O'Keefe DS, Su SL, Bacich DJ, et al: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443:113-127, 1998
44. Xiao Z, Adam BL, Cazares LH, et al: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61:6029-6033, 2001
45. Rosenthal SA, Haseman MK, Polascik TJ: Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 7:27-37, 2001
46. Hunink MGM, Krestin GP: Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology. Radiology 222:604-614, 2002
47. Hillman BJ: Outcomes research and cost-effectiveness analysis for diagnostic imaging. Radiology 193:307-310, 1994